Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype
Summary Asthma is underdiagnosed and undertreated in China, where treatment with dupilumab could be beneficial. In this industry‐funded post hoc exploratory analysis, dupilumab showed clinical efficacy in allergic and non‐allergic asthma.
Authors
- Qingling Zhang (ORCID: https://orcid.org/0000-0002-2433-2849)
- Jérôme Msihid (ORCID: https://orcid.org/0000-0003-4733-5855)
- Zhenan Deng (ORCID: https://orcid.org/0000-0002-8603-728X)
- Jie Lin (ORCID: https://orcid.org/0000-0001-6351-3389)
- Haohui Fang
- Jason H. Kwah (ORCID: https://orcid.org/0000-0003-3119-4939)
- Yvonne Huang
- Nanshan Zhong (ORCID: https://orcid.org/0000-0003-2274-1427)
- Olivier Ledanois (ORCID: https://orcid.org/0009-0007-7570-8942)
- Xiuhua Fu
Institutions
- Regeneron (United States) (US)
- Wenzhou Medical University (CN)
- Sanofi (France) (FR)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (CN)
- Sanofi (China) (CN)
- Guangzhou Laboratory (CN)
- Inner Mongolia Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-11-04
- DOI
- https://doi.org/10.1111/cea.70462
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00